A First Human Study of a Ferroportin Antibody

Phase 1 Completed 32 enrolled Eli Lilly and Company

RandomizedParallel-groupSingle-blindBasic science

Summary

The purposes of this study are to evaluate the following in healthy participants: 1) LY2928057 safety, including any side effects possibly associated with LY2928057; 2) how the body processes LY2928057; 3) effect of LY2928057 on blood iron levels; and 4) immune system reactions to LY2928057.

Timeline

Start: 2011-03
Primary completion: 2011-09
Completion: 2011-09

Publications

Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol. 2019 May;85(5):935-948. doi: 10.1111/bcp.13877. Epub 2019 Mar 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2928057	Monoclonal antibody	30 mg	Intravenous
Subject	LY2928057	Monoclonal antibody	100 mg	Intravenous
Subject	LY2928057	Monoclonal antibody	300 mg	Intravenous
Subject	LY2928057	Monoclonal antibody	1000 mg	Intravenous

Indications

No indication recorded.